|
Outcome variables
|
MHT users
|
Non-users
|
HR
|
95% CI
|
P
|
|---|
|
n
|
Rateb
|
n
|
Rateb
|
|---|
|
All-cause mortality
|
333
|
0.238
|
2173
|
0.314
|
0.784
|
0.698, 0.880
|
< .0001
|
|
Cancer-related mortality
|
115
|
0.082
|
661
|
0.096
|
0.874
|
0.717, 1.066
|
0.1843
|
|
Mortality from GI cancer
|
50
|
0.036
|
338
|
0.049
|
0.737
|
0.547, 0.993
|
0.0445
|
|
Gastric
|
7
|
0.005
|
86
|
0.012
|
0.411
|
0.190, 0.890
|
0.0240
|
|
Colorectal
|
3
|
0.002
|
81
|
0.012
|
0.181
|
0.057, 0.572
|
0.0036
|
|
Hepatobiliary
|
26
|
0.019
|
121
|
0.018
|
1.077
|
0.704, 1.647
|
0.7332
|
|
Pancreatic
|
13
|
0.009
|
48
|
0.007
|
1.333
|
0.721, 2.463
|
0.3598
|
- Other covariates (age group, income, region, Charlson comorbidity index, and year of study entry) were adjusted in each survival analysis
- CI confidence interval, GI gastrointestinal, HR hazard ratio, MHT menopausal hormone therapy
- aAdjusted hazard ratios for mortality in MHT users compared to non-users
- bMortality rates per 100,000 person-years
